Advanced Malignant Solid Tumors Clinical Trial
Official title:
A Multicenter, Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-653 in Treatment of Patients With Advanced Malignant Solid Tumors and Tenosynovial Giant Cell Tumor
To evaluate the safety and tolerability of HMPL-653 in patients with advanced solid tumors who have failure of standard of care or can not tolerate standard of care or those with TGCT, and to determine the maximum tolerated dose (MTD) and/or the recommended phase II clinical study dose (RP2D) of HMPL-653 in patients with advanced solid tumors.
Status | Recruiting |
Enrollment | 113 |
Est. completion date | April 14, 2025 |
Est. primary completion date | June 28, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Able to understand and willing to sign the ICF. 2. Aged 18 to 75 years. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Life expectancy at least 12 weeks. 5. Adequate bone marrow, liver and kidney function. Exclusion Criteria: 1. Toxicity associated with previous antitumor therapy not recovered to =CTCAE grade 1; 2. Previous treatment with anti-CSF1R therapy and have progressive disease; 3. Receiving approved systematic antitumor therapy or in the treatment period of other interventional clinical study within 4 weeks prior to the first dose. 4. Patients with central nervous system (CNS) malignant tumor or malignant solid tumor with known CNS metastasis; 5. Pregnant or lactating women. |
Country | Name | City | State |
---|---|---|---|
China | Jilin Provincial Cancer Hospital | Chang chun | |
China | Harbin Medical University Cancer Hospital | Harbin | |
China | Linyi Cancer Hospital | Linyi | |
China | Henan Cancer Hospital | Zhengzhou | |
China | The First Affiliated Hospital of Zhengzhou University | Zhengzhou |
Lead Sponsor | Collaborator |
---|---|
Hutchison Medipharma Limited |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurrence of Dose-Limiting Toxicities(DLTs) | To evaluate the safety and tolerability of HMPL-653 for dose escalation period | up to 33 days | |
Primary | Maximum tolerated dose (MTD) | The Maximum tolerated dose of HMPL-653 | up to 12 months | |
Primary | Recommended phase II dose (RP2D) | Recommended phase II dose of HMPL-653 | up to 12 months | |
Secondary | Pharmacokinetic-Cmax | Peak concentration of Pharmacokinetic | up to 9 weeks | |
Secondary | Pharmacokinetic-Tmax | Time to peak concentration of Pharmacokinetic | up to 9 weeks | |
Secondary | Pharmacokinetic-Ctrough | Trough concentration of Pharmacokinetic | up to 9 weeks | |
Secondary | Pharmacokinetic-t1/2 | Terminal elimination half-life of Pharmacokinetic | up to 9 weeks | |
Secondary | Pharmacokinetic-AUC0-t | Area under the plasma concentration-time curve of Pharmacokinetic | up to 9 weeks | |
Secondary | Pharmacokinetic-AUC0-8 | Area under the plasma concentration-time curve of Pharmacokinetic | From first dose up to C3D1, estimated up to 9 weeks | |
Secondary | Pharmacokinetic-AUC0-t | Area under the plasma concentration-time curve of Pharmacokinetic | up to 9 weeks | |
Secondary | Pharmacokinetic-CL/F | Apparent clearance of Pharmacokinetic | up to 9 weeks | |
Secondary | Pharmacokinetic-Vz/F | Apparent volume of distribution in the terminal phase of Pharmacokinetic | up to 9 weeks | |
Secondary | Pharmacokinetic-AR | AUC-based accumulation coefficient of Pharmacokinetic | up to 9 weeks | |
Secondary | Objective response rate (ORR) | The incidence of confirmed complete response or partial response. | 12 months | |
Secondary | Progression-free survival (PFS) | The time from the first dose of study treatment to PD or death for any reason, whichever comes first. | 12 months | |
Secondary | Disease control rate (DCR) | The proportion of patients with confirmed CR or PR or stable disease (SD) as the best response, and the duration of SD needs to be =6 weeks. | 12 months | |
Secondary | Time to response (TTR) | The time from the first dose of HMPL-653 to the first objective response. | 12 months | |
Secondary | Duration of response (DoR) | The time from the first appearance of confirmed CR or PR to PD or death for any reason (whichever comes first), in the patients with objective response. | 12 months | |
Secondary | Overall survival (OS) | The time from the first dose of study treatment to death for any reason. | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00728468 -
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
|
Phase 1 | |
Completed |
NCT00445458 -
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00768469 -
Study Evaluating Safety And Tolerability, Solid Tumor
|
Phase 1 | |
Recruiting |
NCT04226066 -
Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04908046 -
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06464055 -
A Study of GQ1010 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06231550 -
A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05383703 -
Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor
|
Phase 1 | |
Recruiting |
NCT05773937 -
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
|
Phase 1 | |
Completed |
NCT04328506 -
Bioequivalency Study of CM082 Tablet in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT05886374 -
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Completed |
NCT00958724 -
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05949775 -
Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
|
N/A | |
Terminated |
NCT02045095 -
A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00884845 -
Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03792958 -
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT00997360 -
Study of PKI-179 Administered Orally to Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT04126668 -
A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT05338957 -
A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.
|
Phase 1/Phase 2 | |
Recruiting |
NCT03047811 -
The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors
|
N/A |